Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2019-05-10 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
第一期员工持股计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a draft summary of an employee stock ownership plan (员工持股计划草案) for 普洛药业股份有限公司. It details the purpose, principles, participants, funding, stock sources, lock-up periods, management, changes, termination, and procedural steps of the employee stock ownership plan. It references relevant laws and regulations, the company's board and shareholder meetings, and includes detailed governance and operational rules for the plan. There is no indication that this is a financial report, earnings release, or regulatory filing announcement. Instead, it is a detailed plan document related to capital structure and employee shareholding. This fits best under the category of Capital/Financing Update (CAP), as it concerns the company's financing activities through an employee stock ownership plan, including share acquisition and management of shares by employees.
2019-05-10 Chinese
监事会关于公司第一期员工持股计划相关事项的书面意见
Regulatory Filings Classification · 95% confidence The document is a written opinion from the Supervisory Board regarding the company's first employee stock ownership plan. It discusses compliance with laws and regulations, benefits of the plan, and procedural legitimacy. It does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. It is not a management change, earnings release, or any other specific report type. This type of document is best classified as a Regulatory Filing (RNS) because it is a formal regulatory disclosure related to corporate governance and employee stock plans but does not fit other categories.
2019-05-10 Chinese
第七届监事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 12th meeting of the 7th Supervisory Board of 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.). It details the approval of an employee stock ownership plan and its management measures, including voting results and compliance with relevant laws. The document is short (1149 characters) and serves as a public disclosure of board decisions rather than a full report or financial statement. It does not contain financial data, earnings, or detailed management discussion. It is not a report publication announcement since it contains substantive content about the meeting resolutions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2019-05-10 Chinese
第一期员工持股计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of an employee stock ownership plan (员工持股计划) for 普洛药业股份有限公司. It includes comprehensive information about the plan's purpose, participants, funding, management, rights and obligations, risk warnings, and procedural steps including board and shareholder approvals. The document is lengthy (15,000 characters) and contains substantive content about the plan itself, not just an announcement or summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a detailed plan document related to capital structure and employee shareholding. According to the filing definitions, this fits best under Capital/Financing Update (CAP) because it concerns company fundraising and capital structure changes through an employee stock ownership plan.
2019-05-10 Chinese
独立董事第七届董事会第十五次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 普洛药业股份有限公司 regarding the company's employee stock ownership plan. It references relevant laws and regulations and confirms the legality and appropriateness of the plan. The document is a formal opinion related to board matters and employee stock plans, not a full financial report, earnings release, or regulatory filing. It is not a report publication announcement or certification. The content aligns with board/management information about governance and internal company decisions. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is short and focused on board opinions, supporting this classification.
2019-05-10 Chinese
关于召开2019年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2019 first extraordinary general meeting of shareholders for 普洛药业股份有限公司. It includes details about the meeting date, voting procedures, proposals to be discussed, and instructions for shareholders to participate and vote. There is no financial data, earnings information, or report content. It is an announcement related to a shareholder meeting, specifically a notice of the meeting and voting instructions. This fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2019-05-10 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.